Literature DB >> 27511006

Compartment-Dependent Degradation of Mutant Huntingtin Accounts for Its Preferential Accumulation in Neuronal Processes.

Ting Zhao1, Yan Hong1, Shihua Li2, Xiao-Jiang Li3.   

Abstract

UNLABELLED: In neurodegenerative diseases caused by misfolded proteins, including Huntington's disease (HD), the neuronal processes and terminals are particularly prone to the accumulation of misfolded proteins, leading to axonal and synaptic dysfunction. This compartment-dependent accumulation can result from either the altered transport of misfolded proteins or impaired protein degradation. Mutant huntingtin (mHtt), the HD protein, is known to affect intracellular transport and can be degraded by the proteasome and autophagy, but how mHtt accumulates in the neuronal processes, an early pathological event in the brains of HD patients, still remains unclear. Using an "optical pulse-chase" assay that can quantify protein degradation in specific subcellular regions, we found that neuronal mHtt is removed faster in the cell body than in neurites. Furthermore, mHtt is cleared more rapidly in astrocytes than in neurons. The ubiquitin-proteasome system plays a much bigger role than autophagy in degrading soluble mHtt via K48 ubiquitination in both the cytoplasm and processes of neurons and astrocytes. By injecting adenoviral vectors expressing mHtt into the mouse brain, we confirmed that mHtt is removed more slowly in neurites than in the cytoplasm of the cell body of neurons. Our findings provide evidence for the cell type- and compartment-dependent degradation of mHtt and explain why mHtt preferentially accumulates and aggregates in the neuropils of vulnerable neurons. In addition, our findings suggest that enhancing proteasomal activity could be an effective way to reduce the preferential accumulation of soluble mHtt in neuronal processes. SIGNIFICANCE STATEMENT: The clearance of misfolded proteins is key to preventing neurodegeneration in Huntington's disease, but how mutant huntingtin (mHtt) accumulates differentially in different cell types and subcellular regions remains unclear. We found mHtt is cleared slowly in neuronal processes compared with the cytoplasm and is cleared more efficiently in astrocytes than in neurons. Moreover, this compartment-dependent degradation of soluble mHtt is mediated primarily by the ubiquitin-proteasome system rather than autophagy. Our findings imply that enhancing proteasome activity could be an efficient way to clear soluble misfolded proteins in the neuronal processes.
Copyright © 2016 the authors 0270-6474/16/368317-12$15.00/0.

Entities:  

Keywords:  clearance; degradation; misfolding; neurodegeneration; polyglutamine; subcellular

Mesh:

Substances:

Year:  2016        PMID: 27511006      PMCID: PMC4978797          DOI: 10.1523/JNEUROSCI.0806-16.2016

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  37 in total

Review 1.  Protein degradation and protection against misfolded or damaged proteins.

Authors:  Alfred L Goldberg
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

Review 2.  Ubiquitin: structures, functions, mechanisms.

Authors:  Cecile M Pickart; Michael J Eddins
Journal:  Biochim Biophys Acta       Date:  2004-11-29

3.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

Review 4.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

Review 5.  Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease.

Authors:  P Hemachandra Reddy; Ulziibat P Shirendeb
Journal:  Biochim Biophys Acta       Date:  2011-11-04

6.  Dynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy: association with sequestosome 1/p62.

Authors:  Natura Myeku; Maria E Figueiredo-Pereira
Journal:  J Biol Chem       Date:  2011-05-02       Impact factor: 5.157

Review 7.  Molecular mechanisms and potential therapeutical targets in Huntington's disease.

Authors:  Chiara Zuccato; Marta Valenza; Elena Cattaneo
Journal:  Physiol Rev       Date:  2010-07       Impact factor: 37.312

8.  Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice.

Authors:  H Li; S H Li; Z X Yu; P Shelbourne; X J Li
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

9.  Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms.

Authors:  Qiaoqiao Xu; Shanshan Huang; Mingke Song; Chuan-En Wang; Sen Yan; Xudong Liu; Marta A Gaertig; Shan Ping Yu; He Li; Shihua Li; Xiao-Jiang Li
Journal:  J Cell Biol       Date:  2013-09-30       Impact factor: 10.539

Review 10.  Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.

Authors:  Aaron Ciechanover; Yong Tae Kwon
Journal:  Exp Mol Med       Date:  2015-03-13       Impact factor: 8.718

View more
  23 in total

Review 1.  Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.

Authors:  Amanda K Davis; William B Pratt; Andrew P Lieberman; Yoichi Osawa
Journal:  Cell Mol Life Sci       Date:  2019-09-24       Impact factor: 9.261

2.  Differential HspBP1 expression accounts for the greater vulnerability of neurons than astrocytes to misfolded proteins.

Authors:  Ting Zhao; Yan Hong; Peng Yin; Shihua Li; Xiao-Jiang Li
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-28       Impact factor: 11.205

3.  Nmnat restores neuronal integrity by neutralizing mutant Huntingtin aggregate-induced progressive toxicity.

Authors:  Yi Zhu; Chong Li; Xianzun Tao; Jennifer M Brazill; Joun Park; Zoraida Diaz-Perez; R Grace Zhai
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-04       Impact factor: 11.205

4.  Inhibition of p38 Mitogen-Activated Protein Kinase Ameliorates HAP40 Depletion-Induced Toxicity and Proteasomal Defect in Huntington's Disease Model.

Authors:  Zih-Ning Huang; Jie-Mao Chen; Liang-Ching Huang; Yi-Hsuan Fang; Lu-Shiun Her
Journal:  Mol Neurobiol       Date:  2021-01-25       Impact factor: 5.590

5.  Differential expression and roles of Huntingtin and Huntingtin-associated protein 1 in the mouse and primate brains.

Authors:  Xingxing Chen; Yize Sun; Laiqiang Chen; Xiu-Sheng Chen; Mingtian Pan; Yiran Zhang; Qi Wang; Weili Yang; Peng Yin; Dajian He; Xiangyu Guo; Su Yang; Yan Zeng; Sen Yan; Xiao-Jiang Li; Shihua Li
Journal:  Cell Mol Life Sci       Date:  2022-10-17       Impact factor: 9.207

6.  Mutant Huntingtin Inhibits αB-Crystallin Expression and Impairs Exosome Secretion from Astrocytes.

Authors:  Yan Hong; Ting Zhao; Xiao-Jiang Li; Shihua Li
Journal:  J Neurosci       Date:  2017-09-11       Impact factor: 6.167

Review 7.  Cell-Autonomous and Non-cell-Autonomous Pathogenic Mechanisms in Huntington's Disease: Insights from In Vitro and In Vivo Models.

Authors:  Jordi Creus-Muncunill; Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

8.  Involvement of Astrocytes and microRNA Dysregulation in Neurodegenerative Diseases: From Pathogenesis to Therapeutic Potential.

Authors:  Yang Bai; Xing Su; Lianhua Piao; Zheng Jin; Rihua Jin
Journal:  Front Mol Neurosci       Date:  2021-03-17       Impact factor: 5.639

Review 9.  Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.

Authors:  Falguni Baidya; Mariya Bohra; Aishika Datta; Deepaneeta Sarmah; Birva Shah; Priya Jagtap; Swapnil Raut; Ankan Sarkar; Upasna Singh; Kiran Kalia; Anupom Borah; Xin Wang; Kunjan R Dave; Dileep R Yavagal; Pallab Bhattacharya
Journal:  Immunology       Date:  2020-10-06       Impact factor: 7.397

10.  Insulin-like growth factor 2 (IGF2) protects against Huntington's disease through the extracellular disposal of protein aggregates.

Authors:  Paula García-Huerta; Paulina Troncoso-Escudero; Di Wu; Arun Thiruvalluvan; Marisol Cisternas-Olmedo; Daniel R Henríquez; Lars Plate; Pedro Chana-Cuevas; Cristian Saquel; Peter Thielen; Kenneth A Longo; Brad J Geddes; Gerardo Z Lederkremer; Neeraj Sharma; Marina Shenkman; Swati Naphade; S Pablo Sardi; Carlos Spichiger; Hans G Richter; Felipe A Court; Kizito Tshitoko Tshilenge; Lisa M Ellerby; R Luke Wiseman; Christian Gonzalez-Billault; Steven Bergink; Rene L Vidal; Claudio Hetz
Journal:  Acta Neuropathol       Date:  2020-07-08       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.